Agilent joins NIIMBL to support for biologics manufacturability and Industry 4.0 initiatives

Agilent Technologies Inc. has joined the National Institute for Innovation in Manufacturing to Advance Biomanufacturing (NIIMBL). Membership in NIIMBL demonstrates Agilent’s commitment to supporting biopharma and biotherapeutics customer challenges through partnership and innovation using tools and workflows. The biomanufacturing industry is increasingly interested in continuous manufacturing solutions that can reduce the manufacturing footprint and improve supply chain logistics and biotherapeutic access by enabling manufacturing to move closer to patients, especially in underserved areas. The NIIMBL’s mission is to accelerate biopharmaceutical innovation, support the development of standards that enable more efficient and rapid manufacturing capabilities, and educate and train a world-leading biopharmaceutical manufacturing workforce, which will fundamentally advance US competitiveness in the industry.